Beatson Institute For Cancer Research
Latest income
£33.4m
Latest spending
£34.2m
Accounts read
FY2026
Form
Company (the charity is registered with Companies House)
Financial health, per FY2026 accounts
The accounts state that the charity reported a decrease in funds of £0.8M for the year, with total expenditure of £34.2M against income of £33.4M. Per the trustees' report, the Institute remains in a strong financial position with sufficient free reserves and healthy cash balances, supported by a seven-year core funding commitment from Cancer Research UK.
What the accounts disclose
Reserves policy: one to three months total running costs (held: £13.8m)
“the Directors seek to maintain unrestricted reserves within a range of one to three months total running costs.” — page 12
Per FY2026 accounts as filed with OSCR.
Largest income source: Research grants (89% of income)
“Grants from Cancer Research UK 21,055”
Per FY2026 accounts as filed with OSCR.
Fundraising cost ratio: 0.0% of fundraised income
“The Institute does not actively raise funds and, as a result, incurs no such costs.”
Per FY2026 accounts as filed with OSCR.
Trading subsidiary: Beatson Technology Ltd
“Beatson Technology Ltd is a wholly-owned subsidiary company, registered in Scotland (Company No SC192461) and established to undertake commercial developments arising as a by-product of the Institute’s charitable medical research activities.” — page 14
Per FY2026 accounts as filed with OSCR.
Independent examiner: PricewaterhouseCoopers LLP
Per FY2026 accounts as filed with OSCR.